VRTX vs REGN
VRTX and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $130.87B | — |
| P/E (TTM) | 30.1 | 19.5 |
| P/B | 6.46 | — |
| P/S | 10.9x | — |
| Revenue | $12.59B(TTM) | $15.53B(TTM) |
| Revenue growth (YoY) | 8.9% | 1.0% |
| Net income | $4.41B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | 838.1% | 2.1% |
| EPS, diluted | $17.17(TTM) | $40.41(TTM) |
| EBIT margin | 34.8% | 24.9% |
| ROE | 19.5% | 14.2% |
| ROIC | 25.0% | 9.4% |
| 1y total return | +33.5% | +34.8% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs REGN
| Metric | VRTX | REGN |
|---|---|---|
| End value | $62.9K | $20.3K |
| Total return | +528.6% | +103.3% |
| CAGR | +19.5% | +7.1% |
| Volatility | 32.7% | 32.0% |
| Sharpe | 0.58 | 0.25 |
| Sortino | 0.86 | 0.36 |
| Max drawdown | -41.6% | -59.7% |
Based on 2600 common trading days, 2016-05-16 → 2026-09-17 · risk-free 4.12% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)